Viewing Study NCT04969861

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:52 AM
Ignite Modification Date: 2026-01-19 @ 9:22 AM
Study NCT ID: NCT04969861
Status: TERMINATED
Last Update Posted: 2023-01-12
First Post: 2021-07-09
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Sponsor: Nektar Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Head and Neck Cancer View
None Recurrent Head and Neck Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Head and Neck Cancer View
None Head and Neck Squamous-Cell Carcinoma View
None HNSCC View
None BEMPEG View
None Bempegaldesleukin View
None NKTR-214 View
None Keytruda View
None Pembrolizumab View
None PROPEL-36 View